THERAPY DOSSIER · th-1bacc000800d

YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28478272 ↗2017Reported benefit

The pivotal role of HIF-1alpha in lung inflammatory injury induced by septic mesenteric lymph.

RatOtherSprague-DawleyMaleIntratracheal delivery

Model: Acute lung injury induced by injection of septic mesenteric lymph

Septic lymph raised lung injury scores, myeloperoxidase and HIF-1alpha expression, and intratracheal YC-1 significantly attenuated the lung inflammatory damage.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…